What smart money is saying about Novonesis
1 fund in our archive has pitched Novonesis — most recently Artisan Global Discovery Strategy in December 2024.
Formerly Novozymes A/S, the company merged with Chr. Hansen in January 2024 to form Novonesis, a leading biosolutions entity. It develops and sells industrial enzymes, microorganisms, and biopharmaceutical ingredients globally. Class B shares are listed separately and trade on European exchanges.
Get an email when a fund writes about it
Fund coverage · 1 thesis
- Artisan Global Discovery StrategyDecember 2024
Novonesis is a global biosolutions powerhouse formed from the merger of Novozym and Chr Hansen, focused on sustainable innovations in consumer products and industrial processes, with strong growth potential driven by effective commercialization and cost synergies.
Read the full thesis
Read every full thesis on Novonesis
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→